Christine Siu

Christine Siu is the Chief Executive Officer, In Residence of CoA Therapeutics. She formerly served as the founding chief operating officer of Eidos. Prior to that, Ms. Siu served as the chief business officer of the Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017. Previously, Christine served as venture principal at Third Rock Ventures, where she helped start Global Blood Therapeutics (GBT), was the first employee there and served as senior director of corporate development from 2012 to 2014. Previously, she held roles of increasing responsibility at private equity and venture capital firms, Warburg Pincus and Thomas, McNerney & Partners, where she invested in life sciences companies. Christine received her B.S. with distinction in cellular molecular biology and economics from the University of Michigan and her MBA from Harvard Business School.